Citadel Advisors’s Tema Oncology ETF CANC Stock Holding History

Citadel Advisors’s Portfolio CANC Stock Details CANC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-69,106	Closed	-$2.54M	–	13764
2026 Q1	$2.54M	Buy	+69,106	New	+$2.52M	﹤0.01%	5589

Other funds holding CANC

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

PIA

Perennial Investment Advisors Los Angeles, California $1.51B AUM 28.71% 1-Year Est. Return

OIM

Oder Investment Management Woodland Hills, California $149M AUM 20.29% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

WWM

WJ Wealth Management Glendale, Arizona $253M AUM 28.6% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Citadel Advisors's CANC Position: Q2 2026 in Review

Citadel Advisors sold out of Tema Oncology ETF (CANC) in Q2 2026, closing a stake of 69,106 shares — an estimated $2.54M sold.

Citadel Advisors first reported a position in CANC in Q1 2026 and held it in 1 quarter. The position peaked at $2.54M in Q1 2026. 15 funds tracked by Wall St. Rank hold CANC as of Q2 2026.

Citadel Advisors reported no remaining Tema Oncology ETF position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 69,106 Tema Oncology ETF shares in Q2 2026, an estimated $2.54M.
Citadel Advisors first reported a position in Tema Oncology ETF in Q1 2026 and held it in 1 quarter.
Citadel Advisors's Tema Oncology ETF position peaked at $2.54M in Q1 2026.
15 funds tracked by Wall St. Rank held Tema Oncology ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.